SAM
VKTX icon

Shell Asset Management’s Viking Therapeutics VKTX Stock Holding History

Shell Asset Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$23K Sell
883
-1,575
-64% -$47K ﹤0.01% 1020
2025
Q2 		$65K Sell
2,458
-270
-10% -$7.11K ﹤0.01% 1102
2025
Q1 		$66K Sell
2,728
-118
-4% -$3.73K ﹤0.01% 1096
2024
Q4 		$115K Hold
2,846
– – 0.01% 1019
2024
Q3 		$180K Buy
+2,846
New +$167K 0.01% 872
2024
Q1 		$160K Buy
+3,009
New +$134K 0.01% 900

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Shell Asset Management's VKTX Position: Q3 2025 in Review

Shell Asset Management reduced its Viking Therapeutics (VKTX) stake by 64% in Q3 2025, selling an estimated $47K and leaving 883 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #1020.

Shell Asset Management first reported a position in VKTX in Q1 2024 and has held it in 6 quarters since. The position peaked at $180K in Q3 2024. 370 funds tracked by Wall St. Rank hold VKTX as of Q3 2025.

  • Shell Asset Management held 883 shares of Viking Therapeutics worth $23K as of Q3 2025.
  • Shell Asset Management sold 1,575 Viking Therapeutics shares in Q3 2025, an estimated $47K.
  • Viking Therapeutics made up ﹤0.01% of Shell Asset Management's portfolio in Q3 2025, its #1020 holding.
  • Shell Asset Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • Shell Asset Management's Viking Therapeutics position peaked at $180K in Q3 2024.
  • 370 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.